Drug survival of IL‐23 and IL‐17 inhibitors versus other biologics for psoriasis: A British Association of Dermatologists Biologics and Immunomodulators Register cohort study
Sign Up to like & getrecommendations! Published in 2025 at "Journal of the European Academy of Dermatology and Venereology"
DOI: 10.1111/jdv.20739
Abstract: Interleukin (IL)‐23p19 and IL‐17 inhibitors have demonstrated high efficacy for psoriasis in randomized controlled trials, though real‐world data, particularly for risankizumab (IL‐23p19 inhibitor) and brodalumab (IL‐17 receptor (IL‐17R) inhibitor), is limited. read more here.
Keywords: drug survival; survival inhibitors; psoriasis british; versus biologics ... See more keywords
Immunotherapy versus biologics as second-line therapy in advanced hepatocellular carcinoma (HCC).
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.4_suppl.533
Abstract: 533Background: Sorafenib or lenvatinib are the current frontline options for advanced HCC. Multiple biologic agents including multi-Tyrosine Kinase Inhibitors (TKI) cabozantinib & regorafenib have ... read more here.
Keywords: biologics second; immunotherapy versus; therapy advanced; versus biologics ... See more keywords
Refractory ulcerative colitis: Upadacitinib versus other biologics
Sign Up to like & getrecommendations! Published in 2024 at "World Journal of Clinical Cases"
DOI: 10.12998/wjcc.v12.i31.6425
Abstract: In this editorial we comment on an article published in World Journal of Clinical Cases in 2024, in which a case of refractory ulcerative colitis (UC) was discussed based on the response to different lines… read more here.
Keywords: refractory ulcerative; versus biologics; ulcerative colitis; colitis upadacitinib ... See more keywords